Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Unresectable Gastric Cancer
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the efficacy and safety of combination of sintilimab
(PD-1 inhibitor) , apatinib and chemotherapy in unresectable advanced gastric cancer patients
with oligo metastasis. This study was designed as single arm with fixed number of
participants.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital